Middle East & Africa Amyloidosis Treatment Market Size & Outlook
MEA amyloidosis treatment market highlights
- The MEA amyloidosis treatment market generated a revenue of USD 206.8 million in 2024.
- The market is expected to grow at a CAGR of 5.7% from 2025 to 2033.
- In terms of segment, chemotherapy was the largest revenue generating treatment in 2024.
- Chemotherapy is the most lucrative treatment segment registering the fastest growth during the forecast period.
MEA data book summary
| Market revenue in 2024 | USD 206.8 million |
| Market revenue in 2033 | USD 348.0 million |
| Growth rate | 5.7% (CAGR from 2025 to 2033) |
| Largest segment | Chemotherapy |
| Fastest growing segment | Chemotherapy |
| Historical data covered | 2021 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Chemotherapy |
| Key market players worldwide | Pfizer Inc, Ionis Pharmaceuticals Inc, Takeda Pharmaceutical Co Ltd, Johnson & Johnson, Alnylam Pharmaceuticals Inc |
Other key industry trends
- In terms of revenue, MEA region accounted for 3.6% of the global amyloidosis treatment market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2033.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 2,797.2 million by 2033.
Key Regions: U.S. , UK , Japan , Brazil , South Africa
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Amyloidosis Treatment Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Alnylam Pharmaceuticals Inc | View profile | 2100 | 675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, United States, 02142 | https://www.alnylam.com |
| Ionis Pharmaceuticals Inc | View profile | 927 | 2855 Gazelle Court, Carlsbad, CA, United States, 92010 | https://www.ionispharma.com |
| Takeda Pharmaceutical Co Ltd | View profile | 49095 | 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan, 103-8668 | https://www.takeda.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
| Johnson & Johnson | View profile | 134400 | One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 | https://www.jnj.com |
Middle East & Africa amyloidosis treatment market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to amyloidosis treatment market will help companies and investors design strategic landscapes.
Chemotherapy was the largest segment with a revenue share of 108.03% in 2024. Horizon Databook has segmented the Middle East & Africa amyloidosis treatment market based on chemotherapy covering the revenue growth of each sub-segment from 2021 to 2033.
Reasons to subscribe to Middle East & Africa amyloidosis treatment market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Middle East & Africa amyloidosis treatment market databook
-
Our clientele includes a mix of amyloidosis treatment market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa amyloidosis treatment market , including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa amyloidosis treatment market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Partial client list
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
